DaVita (DVA) Projected to Post Quarterly Earnings on Thursday

DaVita (NYSE:DVA) will likely be issuing its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of $3.57 per share and revenue of $3.52 billion for the quarter. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 5:00 PM ET.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. During the same period in the prior year, the company earned $2.95 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, analysts expect DaVita to post $14.57 EPS for the current fiscal year and $17.25 EPS for the next fiscal year.

DaVita Price Performance

Shares of DaVita stock opened at $176.65 on Thursday. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $247.49. The firm has a fifty day moving average price of $180.38 and a two-hundred day moving average price of $191.46. The company has a market cap of $11.27 billion, a PE ratio of 14.46, a price-to-earnings-growth ratio of 0.45 and a beta of 0.80.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on DVA. Raymond James Financial set a $220.00 price objective on shares of DaVita in a research report on Friday, August 7th. UBS Group lifted their target price on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Oppenheimer set a $220.00 price objective on DaVita in a research report on Friday, August 7th. Finally, Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 9th. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $233.43.

About DaVita

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.